One orally active small molecule uPA inhibitor upamostat (the prodrug form of WX-UK1) was efficacious in a Phase 2 trial for locally advanced non-resectable pancreatic cancer in combination with gemcitabine showing a 17% increase in 1-year survival over gemcitabine or upamostat alone and an acceptable safety profile [142]. This evidence concerns the gene PLAU and pancreatic neoplasm.